Ensysce Faces New Nasdaq Issue as Deadline Nears
Ensysce Biosciences shares fell in pre-market trading after the company disclosed a Nasdaq warning over possible delisting due to a stockholders’ equity deficit. Ensysce reported negative equity of $669,012 as of March 31, down from $2.9 million at year-end. The company has until July 6 to submit a compliance plan and is also under pressure to lift its share price above $1. ENSC last traded near $0.31 early Tuesday.